Peter Attia Explains How to Evaluate Claims About Peptides
Peter Attia Explains How to Evaluate Claims About Peptides
On 10 August, Peter Attia, the creator and host of The Drive podcast, published an analysis of peptides. He proposes evaluating each claim in relation to the specific molecule, product, dose, indication, and person who might need the drug.
In a new episode of The Drive, Attia begins with a definition: a peptide is a short chain of amino acids. This chemical class includes insulin, which has specific indications and supporting clinical evidence. The market uses the same term for substances claimed to improve energy, healing, and longevity.
“The word itself tells us almost nothing about a molecule’s safety, efficacy, or even scientific plausibility. It is a chemical description, not a mark of quality.”
Attia therefore evaluates each claim using five questions. Does the substance have a known target, meaning a site in the body where it is supposed to act, and is there a plausible chain of events connecting that action to the claimed effect? Has this effect been demonstrated in humans? What formulation and dose were studied, how does the substance behave in the body, and what risks does it pose? Is the balance of benefit and risk appropriate for the particular person and their goal? Is there already a well studied treatment for the same problem?
A study evaluates a specific product, including its composition, purity, dose, and manufacturing method. Its findings apply to the formulation and circumstances that were studied.
As an example, Attia examines BPC-157, a peptide marketed in the wellness industry as a healing agent. Under his framework, he places it among substances without scientific support and applies the same questions about its target, outcomes in humans, dosing, and risk. Personal reports combine any possible effect of the substance with expectations, concurrent treatment, and changes in behavior. A controlled study separates the effect of the drug itself from these other factors.
“A drug that worked for one disease, in one group of people, or at one dose cannot automatically be assumed to work equally well when any of these conditions changes.”
A decision about use requires information about the molecule, product, dose, indication, meaning the disease or condition for which it is used, and the person. If even one of these elements changes, the result of the previous study must be tested in the new setting.